Trending Topic

Illustration of the thought processes in the brain
13 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

The prevalence of unruptured intracranial aneurysms (IAs) is approximately 3% of the population, with incidence on the rise due to the increased utilization of neuro-imaging for diverse objectives.1,2 The average risk of rupture for unruptured IA is estimated to vary from 0.3% to exceeding 15% per 5 years.3 Ruptured IA is the primary aetiology of […]

touchLearning Activities

Speciality Filter

Select Specialty or Clinical Area

Clear All
Update Filters
Close Popup
Mark CompleteCompleted
BookmarkBookmarked

New 48-week data from the ongoing Phase 3 KINECT 4 study evaluating valbenazine for the treatment of tardive dyskinesia (TD) have been presented at the 2025 Psychiatry Update Conference in Chicago. The finding showed the majority of participants reached a defined threshold for remission of TD regardless of underlying psychiatric disorder.

Mark CompleteCompleted
BookmarkBookmarked

The FDA has approved tenecteplase (TNKase) for the treatment of acute ischemic stroke (AIS) in adults, marking the first new stroke-specific thrombolytic approval in nearly three decades. Administered as a single five-second intravenous bolus, tenecteplase allows for faster administration compared to the current standard of care alteplase, which is administered as a bolus-plus-infusion regimen.

Mark CompleteCompleted
BookmarkBookmarked

Brain Awareness Week, taking place from March 10-16, 2025, is a global campaign dedicated to fostering public enthusiasm and support for brain science, organised by the Dana Foundation. Each March, participants worldwide organize imaginative activities that highlight the wonders of the brain and the profound impact of neuroscience on our daily lives.

4 mins
Sponsored Content

Watch this short video animation to learn how genetic mutations in patients with Friedreich ataxia (FA) translate into clinical symptoms.

101 mins
Sponsored Content
touchMEETING HIGHLIGHTS
For HCPs in: Global
This content is sponsored by Alexion, AstraZeneca Rare Disease.

Leading experts discuss clinical evidence and real-world experience with complement inhibition therapy in the rare autoimmune disorders AChR-Ab+ gMG and AQP4-Ab+ NMOSD.

Mark CompleteCompleted
BookmarkBookmarked

The first prenatal treatment for spinal muscular atrophy showed promise in a single case report.

Mark CompleteCompleted
BookmarkBookmarked

In this Q&A, Dianne Gove, PhD, Director for Public Involvement and Ethics at Alzheimer Europe discusses the impact of stigma on the quality of life of people living with dementia, explores strategies for raising awareness and challenging misconceptions, and highlights the role of healthcare professionals and Alzheimer Europe’s key initiatives in combating stigma, including plans for 2025.

Mark CompleteCompleted
BookmarkBookmarked

The Food and Drug Administration (FDA) has approved ONAPGO™ (apomorphine hydrochloride) sublingual film for the treatment of “off” episodes in Parkinson’s disease (PD), providing patients with a new, on-demand therapy to rapidly alleviate motor symptoms when standard medications wear off.

Series of 6
Sponsored Content
touchSeries
For HCPs in: Spain, Belgium, Netherlands, Sweden, Finland, Norway, Denmark, Italy
Hear from your peers about smoldering neuroinflammation and disability. Browse these important smoldering neuroinflammation topics, presented by experts in MS at key global conferences.
50 mins
Sponsored Content
touchMEETING HIGHLIGHTS
For HCPs in: Spain, Belgium, Netherlands, Sweden, Finland, Norway, Denmark and Italy

Sanofi at ECTRIMS 2024. Join MS experts as they examine disability accumulation through the lens of personalised care, biomarkers, and clinical trial design. Hear their perspectives on the complexities of balancing improved relapse management with the ongoing challenge of disability accumulation.

58 mins
Sponsored Content
touchMEETING HIGHLIGHTS
For HCPs in: Spain, Belgium, Netherlands, Sweden, Finland, Norway, Denmark and Italy

Sanofi at EAN 2024. Hear from the experts about our evolving understanding of multiple sclerosis pathophysiology and the role of smoldering neuroinflammation, with a closer look at microglia and BTK.

78 mins
Sponsored Content
touchMEETING HIGHLIGHTS
For HCPs in: Spain, Belgium, Netherlands, Sweden, Finland, Norway, Denmark and Italy

Sanofi at AAN 2024. Join MS experts as they examine the role of smoldering neuroinflammation and its underlying biology, with a closer look at microglia and BTK.

56 mins
Sponsored Content
touchMEETING HIGHLIGHTS
For HCPs in: Spain, Belgium, Netherlands, Sweden, Finland, Norway, Denmark and Italy

Sanofi at ECTRIMS 2023. Explore smoldering neuroinflammation, which results in physical and cognitive disability accumulation, and its impact on your patients.

83 mins
Sponsored Content
touchMEETING HIGHLIGHTS
For HCPs in: Spain, Belgium, Netherlands, Sweden, Finland, Norway, Denmark and Italy

Sanofi at AAN 2023. Explore perspectives on MS disability accumulation in the time of highly effective therapies, the smoldering neuroinflammatory pathway, and CNS biomarkers of the future in this Industry Therapeutic Update.

59 mins
Sponsored Content
touchMEETING HIGHLIGHTS
For HCPs in: Spain, Belgium, Netherlands, Sweden, Finland, Norway, Denmark and Italy

Sanofi at EAN 2023. Learn about the drivers of multiple sclerosis disability accumulation, the unique role of smoldering neuroinflammation, and the role of “big data” in central nervous system biomarkers of the future.

Mark CompleteCompleted
BookmarkBookmarked

As we move through 2025, touchNEUROLOGY remains committed to sharing the latest developments in Parkinson’s disease (PD). Our society partners at Parkinson’s Europe have outlined three key hopes for the year ahead—each representing a crucial step toward better support, understanding and treatment for the Parkinson’s community.

Mark CompleteCompleted
BookmarkBookmarked

The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) is gearing up for its tenth annual Forum, set to take place from February 27 to March 1, 2025, at the Palm Beach County Convention Center and Hilton West Palm Beach in Florida. This year’s theme, “Making Connections,” will emphasize vital links within the brain, between the brain and body, and across the multiple sclerosis (MS) research and clinical communities.

Mark CompleteCompleted
BookmarkBookmarked

Living with multiple sclerosis (MS) can present numerous challenges, and for individuals in rural communities, those challenges can be even more pronounced. In rural areas, access to MS specialists can be limited, and often rural hospitals and clinics are the primary locations where residents seek diagnosis and care for MS.

Load More...
touchNEUROLOGY touchNEUROLOGY

Register Now!

Explore the latest in medical education and stay current in your field. Create a free account to track your learning.

  • Save your progress for video
  • Keep track of your CME credits
  • Add personalised learning notes
  • Receive updates from course leaders and faculty
  • Be the first to hear about new and exciting interactive learning opportunities
Close Popup